Suppr超能文献

原发性胆汁性肝硬化中的骨病:口服25-羟维生素D使骨软化症逆转。

Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D.

作者信息

Reed J S, Meredith S C, Nemchausky B A, Rosenberg I H, Boyer J L

出版信息

Gastroenterology. 1980 Mar;78(3):512-7.

PMID:7351289
Abstract

Bone disease and the response to oral 25-hydroxy-vitamin D were assessed in 7 women with primary biliary cirrhosis utilizing histomorphometric analysis of undecalcified iliac crest bone biopsies. Low serum concentrations of 25-hydroxyvitamin D rose from 9.2 +/- 6.7 (SD) to 151.0 +/- 103.7 ng/ml on oral 25-hydroxyvitamin D therapy (100--200 micrograms daily). On initial biopsy 5 of 7 patients had osteomalacia. Repeat bone biopsy in 6 patients after 6--8 mo of continued therapy revealed significant improvement in bone mineralization as reflected in fractional osteoid surface and relative osteoid volume. Osteomalacia healed in 4, improved in 1, and remained absent in 1. Trabecular bone volume, an index of mineralized bone mass, was diminished in 6 of 7 patients and did not change significantly over the 6--8-mo treatment period. We conclude that oral 25-hydroxyvitamin D corrects vitamin D deficiency and reverses osteomalacia in primary biliary cirrhosis.

摘要

利用未脱钙的髂嵴骨活检组织形态计量学分析,对7例原发性胆汁性肝硬化女性患者的骨病及口服25-羟维生素D的反应进行了评估。口服25-羟维生素D治疗(每日100 - 200微克)时,低血清浓度的25-羟维生素D从9.2±6.7(标准差)ng/ml升至151.0±103.7 ng/ml。初次活检时,7例患者中有5例患有骨软化症。6 - 8个月持续治疗后,6例患者再次进行骨活检显示,骨矿化有显著改善,表现为类骨质表面分数和相对类骨质体积。4例骨软化症愈合,1例改善,1例仍未出现骨软化症。作为矿化骨量指标的小梁骨体积,在7例患者中有6例减少,在6 - 8个月的治疗期间无显著变化。我们得出结论,口服25-羟维生素D可纠正原发性胆汁性肝硬化患者的维生素D缺乏并逆转骨软化症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验